The risk of developing melanomas is also increased by CDK4/cyclin D hyperactivation associated with amplification of cyclin D (18% melanomas) or loss of p16INK4a inhibitor of CDK4/cyclin D (deletion of CDK2NA in 50%–60% metastatic tumours) [176]. The gene discussed is CDK4; the disease is metastatic neoplasm.